Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid's new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
It does work, amazingly. I had Covid a few times and took Paxlovid the last time. It works better than any drug I’ve taken. After taking the first dose, there were no more Covid symptoms within 4-6 hours.
The problem with Paxlovid (besides the cost) is that it gives you a new set of side effects: weird joint and muscle pain, a metallic taste in the mouth, etc. They’re better than Covid though. And it won’t kill you.
Just because it worked for you doesn’t mean that the effectiveness in their trials represents real world numbers. I’m not pulling this out of my ass, I was told this by a medical professional.
There are many types of “medical professionals”. Only a vast minority actually read and interpret trial data.
I’m going to trust my direct experience with the drug (I know it works) and real world studies like below.
Conclusions: This study suggests that in the era of Omicron and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.
Add comment